The short-term effects of low-level laser therapy in the management of breast-cancer-related lymphedema
The short-term effects of low-level laser therapy in the management of breast-cancer-related lymphedema
复制标题
DOI：
10.1007/s00520-010-0888-8
复制
发表时间：
2011-05-01
影响因子：
3.1
通讯作者：
Soran, Atilla
中科院分区：
文献类型：
--
作者：
Dirican, Abuzer;Andacoglu, Oya;Soran, Atilla
乳腺癌相关性水肿（Breast-cancer-related lymphedema，BCRL）是一种慢性疾病，目前尚无明确的治疗方法，但有一些针对性的治疗措施可以减轻肢体肿胀及相关问题。自2007年以来，低强度激光治疗（LLLT）已在美国用于治疗乳房切除术后水肿。本研究的目的是回顾我们在2007年至2009年期间接受LLLT治疗的17例BCRL患者的短期经验。所有患者均经历过至少一种常规治疗方式，如综合物理治疗、手动淋巴引流和/或气动泵治疗。将LLLT添加到患者正在进行的治疗方案中。所有患者均完成了由两个周期组成的LLLT全疗程。所有患者均为女性，中位年龄为51.8（44-64）岁。在LLLT的第一个和第二个周期后，Δ C分别降低了54%（15-85%）和73%（33-100%）。在LLLT的第一个和第二个周期后，17例患者中有14例的运动疼痛平均减轻了40%（0-85%）和62.7%（0-100%）。3例患者LLLT后疼痛无改善。LLLT后13例（76.4%）患者的瘢痕活动度增加，14例（82.3%）患者的肩关节活动度改善。一名患者在LLLT期间发生了蜂窝织炎。当LLLT与标准水肿治疗联合使用时，BCRL患者从LLLT中获得了额外的益处。这些益处包括减少肢体周长、疼痛、增加活动范围和疤痕活动度。此外，在本研究中发现两个周期的LLLT上级一个周期。
Breast-cancer-related lymphedema (BCRL) is a chronic disease, and currently there is no definitive treatment for it. There are some therapeutic interventions targeted to decrease the limb swelling and the associated problems. Low-level laser therapy (LLLT) has been used in the treatment of post-mastectomy lymphedema since 2007 in the US. The aim of this study is to review our short-term experience with LLLT in the treatment of BCRL.Seventeen BCRL patients referred to our lymphedema program between 2007 and 2009 were enrolled in this study. All patients had experienced at least one conventional treatment modality such as complex physical therapy, manual lymphatic drainage, and/or pneumatic pump therapy. LLLT was added to patients' ongoing therapeutic regimen. All patients completed the full course of LLLT consisting of two cycles. The difference between sums of the circumferences of both affected and unaffected arms (Delta C), pain score, scar mobility, and range of motion were measured before and after first and second cycles of LLLT sequentially.All patients were female with a median age of 51.8 (44-64) years. Delta C decreased 54% (15-85%) and 73% (33-100%), after the first and second cycles of LLLT, respectively. Fourteen out of seventeen experienced decreased pain with motion by an average of 40% (0-85%) and 62.7% (0-100%) after the first and second cycle of LLLT, respectively. Three patients had no improvement in pain after LLLT. Scar mobility increased in 13 (76.4%) and shoulder range of motion improved in 14 (82.3%) patients after LLLT. One patient developed cellulitis during LLLT.Patients with BCRL received additional benefits from LLLT when used in conjunction with standard lymphedema treatment. These benefits include reduction in limb circumference, pain, increase in range of motion and scar mobility. Additionally, two cycles of LLLT were found to be superior to one in this study.